Fameglow issues supplemental disclosure on revenue recognition for prepaid treatment packages

• Fameglow issued a supplemental announcement to its fiscal 2023, 2024, 2025 annual reports to add disclosures on revenue recognition for prepaid treatment packages.
• Added disclosure states prepaid treatment packages typically have original contract periods of 1–2 years.
• Updated disclosure indicates unsatisfied performance obligations at period-end are expected to be recognized as revenue over 0–2 years, subject to customer usage patterns.
• Supplemental financial review disclosure clarifies breakage and residual contract liabilities were recognized as revenue, representing less than 10% of revenue for fiscal 2023–2025 and six months ended Sept. 30, 2025.
• Company also disclosed deferred revenue turnover days of about 164, 99, 49, and 37 days for fiscal 2023–2025 and six months ended Sept. 30, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fameglow Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260416-12109119), on April 16, 2026, and is solely responsible for the information contained therein.